EDGAR·FLOW

Aquestive Therapeutics, Inc. — Form 10-Q

Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 28/100
What the filing says
Aquestive Therapeutics entered into a license agreement dated September 18, 2026 with Helix NB LLC for 4,993 sq ft of wet lab and office space (Suite D, 10th floor) at H-1 @ New Jersey Health + Life Science Exchange in New Brunswick, NJ. Fixed license fees: Year 1: $249,650 ($20,804/month); Year 2: $257,139.50 ($21,428/month); Year 3: $264,853.69 ($22,071/month). Security deposit: $62,412.51. Three-year initial term with one optional 36-month renewal at fair market value. Possession date targeted prior to September 30, 2026. Licensee pays proportionate share (3.62%) of operating costs and utilities; landlord provides HVAC, electricity, water, lab-specific infrastructure (acid neutralization, RO/DI water, fume hood exhaust), and 24/7 security.
Why this rating

Routine real estate transaction; ~$772k over 3 years is ~0.26% of $291.6M market cap. Modest facility upgrade, not transformational. Supports ongoing operations but minor relative to company scale.

View original filing on SEC.gov ↗ AQST · stock on Yahoo Finance ↗

See more from November 3, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.